BiovaxID Publications

Breadcrumbs

Home

Cancer Vaccine Technology

BiovaxID®

BiovaxID Publications

Written by Administrator

Thursday, 13 January 2011 18:21

Dr. Stephen Schuster, Director of the Lymphoma Program at the Abramson Cancer Center at The University of Pennsylvania, and BiovaxID investigator, presents at a Lymphoma Research Foundation event.

Last Updated ( Thursday, 15 September 2011 23:07 )

To download BiovaxID Fact Sheet, click here

To download BiovaxID 2009 ASCO Plenary Session Presentation, click here

To download BiovaxID 2010 ASH Phase III Isotype Presentation, click here

BiovaxID Highlights:

Patient-specific vaccine stimulates immune system to target a protein (idiotype) exclusively expressed on malignant B-cells
Exemplary safety data; vaccine trains immune system to selectively seek and destroy only the malignant B-cells, while sparing the healthy cells
Statistically significant Phase III results demonstrate disease-free survival benefit in treatment of follicular lymphoma
Encouraging Phase II results suggest overall survival benefit in treatment of mantle cell lymphoma
Positioned to seek U.S. and international approval pathways

Main Menu

BiovaxID Publications

Phase II Follicular Lymphoma (Nature America, 1999)

Phase II Mantle Cell Lymphoma (Nature Medicine, 2005)

Phase III Follicular Lymphoma (Journal of Clinical Oncology, 2011)

BiovaxID®

Biomanufacturing

Media Center